Strategic and Industrial Partnership for DeepQ-MRI / DeepQ-DCE

QMRI Tech S.r.l. is seeking strategic and industrial partners to support the development and translation of DeepQ-MRI, whose first product is DeepQ-DCE, a proprietary quantitative ultrafast Dynamic Contrast-Enhanced MRI (DCE-MRI) technology initially focused on prostate imaging.

DeepQ-DCE combines ultrafast DCE acquisition, advanced pharmacokinetic modelling and physics-based deep learning to generate proprietary quantitative biomarkers , voxel-wise parametric maps and lesion- and patient-level summaries. The technology is designed to add a quantitative layer to prostate MRI and to complement existing multiparametric MRI and biparametric MRI/artificial-intelligence workflows.

DeepQ-DCE is currently at a pre-commercial validation stage. A first pilot study in 24 patients with PI-RADS ≥3 lesions undergoing biopsy has been completed, and the next development step is prospective multicentre validation.

We are interested in collaborations with MRI manufacturers, medical-imaging and software companies, contrast-media companies, diagnostic networks, MedTech organisations and other industrial partners interested in quantitative imaging biomarkers and advanced MRI.

Potential areas of cooperation include co-development, sponsored clinical validation, acquisition-protocol optimisation, software and workflow integration, multicentre standardisation, research-use applications, technology transfer and the definition of future commercialisation models.

The partnership may initially focus on DeepQ-DCE and may subsequently support the broader development of the DeepQ-MRI quantitative imaging platform and its potential extension to additional oncology applications.